Navidea Biopharmaceuticals Inc (NAVB)

[casperboo]

Fred is a short seller of NAVB stock that is great friends with Brent Larson. The following message is an email from Brent to Fred.

Hey Fred.

I know you were disappointed that the European Lymphoseek Cold Kits will be selling in Europe for $100. I tried to get Gonzalez to approve the selling price to be $30. We really slammed it to the shareholder going with Cardinal to sell our $300 product by giving them $150 for each dose. Too bad we didn't make it $225 to Cardinal/$75 to Navidea. You may recall that in the US, I wanted to sell Lymphoseek for $140 per dose, but Pykett was afraid that even the SEC might investigate why we sold a newly approved product for so little. The vouchers did some damage to the stock price, but not enough. Speaking for myself, I can't wait for the pps to slide under 1.00 again because I'm already drafting several PRs to keep it under 1.00 forever, and only continue to fall to our desired covering range. RIGS is going to be formally abandoned first (you knew it 6 years ago of course and were able to short confidently no matter how high or low the NAVB pps got). To really ruin loyal shareholders, you also already know that 4694 and 5001 are due to be formally abandoned in
February simultaneously. This coming PR will reveal that the Crede deal was really for nothing EXCEPT to damage the shareprice. Hopefully the NAVB death spiral will be super severe and you can cover your 12.4 million share short position under 0.29 per share.

Thanks for the $3.7 million I have already been paid to destroy the company that is stupid enough to pay me $250K annually plus bonuses. I look forward the the remaining $4.9 million installment. When the company completely evaporates in a few years, I have $400 per week in unemployment to look forward to as well. I know the current pps of 1.25 is way too high, but just give it time and keep shorting. Our pps will stay under 1.00 and then .50 soon enough.

Life is great for those that know the reality of Navidea.

Always,
Brent